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Abstract
Background: The Polycomb group (PcG) genes are a class of regulators responsible for maintaining homeotic gene
expression throughout cell division. PcG expression is deregulated in some types of human cancer. Both Bmi-1 and
Mel-18 are of the key PcG proteins. We investigate the expression and clinicopathological roles of Mel-18 and Bmi-1
mRNA in gastric cancer.
Methods: The expression of Mel-18 and Bmi-1 in a series of 71 gastric cancer tissues and paired normal mucosal
tissues distant from the tumorous lesion was assayed by quantitative real time RT-PCR. The correlation between
Mel-18 and Bmi-1 mRNA expression, and between Mel-18 or Bmi-1 mRNA level and clinicopathological
characteristics were analyzed.
Results: Expression of Mel-18 and Bmi-1 genes was variably detected, but overexpression of Bmi-1 mRNA and
decreased expression of Mel-18 mRNA were the most frequent alteration. In addition, the expression of Bmi-1 and
Mel-18 mRNA inversely correlates in gastric tumors. Moreover, a significant positive correlation between Bmi-1
overexpression and tumor size, depth of invasion, or lymph node metastasis, and a significant negative correlation
between Mel-18 low-expression with lymph node metastasis or the clinical stage were observed.
Conclusion: Our data suggest that Mel-18 and Bmi-1 may play crucial but opposite roles in gastric cancer.
Decreased Mel-18 and increased Bmi-1 mRNA expression was associated with the carcinogenesis and progression
of gastric cancer. It is possible to list Bmi-1 and Mel-18 as biomarkers for predicting the prognosis of gastric cancer.
Background
The Polycomb group (PcG) genes were first identified in
Drosophila as a class of regulators responsible for main-
taining homeotic gene expression throughout cell divi-
sion [1], PcG genes are conserved from Drosophila to
mammals, and the expression levels of mammalian PcG
genes differ between different tissues and cell types [2],
PcG genes act as epigenetic silencers during embryo
morphogenesis with a central role in the nervous sys-
tem, heart, and skeleton development [3-7].In addition,
PcG members have been involved in the regulation of
such adult processes as the cell cycle, X-inactivation,
and hematopoiesis [8-14]. PcG expression is deregulated
in some types of human cancer [15].Moreover, several
PcG genes may regulate the self-renewal of specific stem
cell types, suggesting a link between the maintenance of
cell homeostasis and carcinogenesis [16,17].
Bmi-1 is one of the key PcG proteins. It was initially
identified as an oncogene that cooperated with c-Myc in
the generation of mouse pre-B-cell lymphomas. It is
also considered the first functional mammalian PcG pro-
tooncogene to be recognized, and it has been implicated
in axial patterning, hematopoiesis, cell cycle regulation,
and senescence [18-21]. Human Bmi-1 gene is located
at the short arm of chromosome 10p13 [22], The region
is involved in chromosomal translocations in leukemia
and is amplified in non-Hodgkin’s lymphoma as well as
in solid tumors [23]. Bmi-1 induces S-phase entry by
inhibiting Rb function via repression of the INK4a/ARF
locus [24-26]. Moreover, overexpression of Bmi-1 in
mammary epithelial cells may activate telomerase and
lead to immortalization [27]. Overexpression of Bmi-1
has been found in several human malignancies including
breast cancer, colorectal cancer, nasopharyngeal carci-
noma, melanoma, gastric cancer, and bladder
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any medium, provided the original work is properly cited.cancer [28-33]. Overexpression of Bmi-1 often correlates
with poorer prognosis and treatment failure [30,32-34].
Bmi-1 also plays an important role in self-renewal of
hematopoietic stem cells, neural stem cells and mam-
mary stem cells [35-37].
In addition to Bmi-1, mammalian cells also express a
Bmi-1-related PcG protein Mel-18. The Mel-18 gene
product is structurally highly similar to Bmi-1 protein.
Interestingly, we have found that Bmi-1 is negatively
regulated by Mel-18 and expression of Mel-18 negatively
correlates with Bmi-1 in breast tumors, and Mel-18
overexpression in breast cancer cell line MCF7 results
in downregulation of Bmi-1 and reduction of trans-
formed phenotype [38]. Negative correlation between
Bmi-1 and Mel-18 expression was also recently reported
in hematopoietic stem cells [39]. Lee et al. also recently
reported that overexpression of Mel-18 inhibits growth
of breast cancer cells [40]. These data suggested that
Mel-18 acts as a potential tumor suppressor. However,
the function of Mel-18 is still debatable. In few other
studies, it was found that similar to Bmi-1, Mel-18 can
act as an oncogene [41,42]. So, the role of Mel-18 in
cancers other than breast cancers and different patholo-
gical conditions is still not clear and need to be clarified.
Gastric cancer is one of the most common malignan-
cies throughout the world. It has been reported that
Bmi-1 is overexpressed in gastric cancer and is an inde-
pendent prognosis factor [32]. We have also studied the
expression of Mel-18 and Bmi-1 in gastric tumors by
immunohistochemistry (IHC). We found that gastric
tumor tissues expressed significantly higher Bmi-1 and
lower Mel-18, and the expression of Mel-18 negatively
correlated with Bmi-1; there was a significant positive
correlation between Bmi-1 expression with lymph node
metastasis, or clinical stage, but there was no obvious
correlation between Mel-18 expression and clinico-
pathological factors; downregulation of Bmi-1 by Mel-18
overexpression or knockdown of Bmi-1 expression was
accompanied by decreased transformed phenotype and
migration ability in gastric cancer cell lines in in vitro
study [33]. So, the results of Bmi-1 expression correlated
with lymph node metastasis or clinical stage in in vivo
study was accordance with the results in in vitro study,
while the results of no correlation was found between
Mel-18 expression and clinicopathological factors in in
vivo study was not accordance with the results in in
vitro study, we suspected that one of the reason may
due to the reliability of IHC method which was used to
detect the expression of Bmi-1 and Mel-18 in tumor tis-
sues in most paper of literature including our previous
study. This method lacks standard procedure and eva-
luation criterion and its’ reliability depends on the speci-
fic of antibody. The results of quantitative Real time
RT-PCR (QRT-PCR) with specific primer is more
reliable than that of IHC to measure the gene expres-
sion level especially for Mel-18, which lacks specific
mouse monoclonal antibody till now. Here, we examine
the expression of Mel-18 and Bmi-1 at mRNA level by
using QRT-PCR method in a series of gastric cancer,
and evaluate the correlation between Mel-18 and Bmi-1
expression levels. Furthermore, a correlation study
between expression levels of both the analyzed genes
and several clinical pathologic variables of the tumors
was designed. In this study, we characterized the expres-
sion profile of Mel-18 and Bmi-1, and their clinical sig-
nificance in gastric cancer.
Materials and methods
Clinical samples
Human gastric cancer samples were obtained from
patients who underwent surgery for gastric cancer in
our hospital from 2007 to 2008. All of the patients
didn’t receive prior chemotherapy or radiotherapy before
surgery. A total of 71 fresh gastric tissues and paired
normal mucosal tissues distant from the tumorous
lesion were removed and frozen in liquid nitrogen and
stored at -80°C until further use. After the diagnosis of
gastric cancer was confirmed, RNA was extracted with
Trizol reagent (Invitrogen) according to the manufac-
turer’s protocol from the cancerous and paired normal
tissues for further RT-PCR analysis of Mel-18 and
Bmi-1 expression. By pathological types, all cases of gas-
tric cancer are adenocarcinomas.
The clinicopathologic variables were obtained from
the medical records and the disease stages of the
patients were classified according to the 2002 UICC gas-
tric cancer TNM staging system. Prior patients’ consent
and approval from the Institute Research Ethics Com-
mittee were obtained for the use of clinical materials
described in the present study.
Quantitative real time RT-PCR (QRT-PCR) assays
The QRT-PCR was carried out as described using Brilli-
a n tS Y B RG r e e nQ R T - P C RM a s t e rM i x ,2 - S t e pk i t
(Stratagene, La Jolla, CA) [43]. cDNA was synthesized
using reverse transcriptase, and the PCR amplification
was carried out using PTC-200 Real Time PCR system
(MJ Research Inc, USA). The primers for QRT-PCR
were Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)f o r w a r d( F ) - 5 ’ GCTGAACGGGAAGCTCA
CTG-3’,GAPDH reverse (R)- 5’GTGCTCAGTGTAGCC
CAGGA3’; Bmi-1 F5 ’ GCTTCAAGATGGCCGCTTG
3’,Bmi-1 R 5’-TTCTCGTTGTTCGATGCATTTC-3’;
and Mel-18 F5 ’- GATGGATGTGCCCAGCAAGT-3’,
Mel-18 R 5’GGAGCCTTGT CGCTGACTGA-3’.A l l
reactions were done in a 20-μl reaction volume in bipli-
cate. PCR amplification consisted of 10 min of an initial
denaturation step at 95°C, followed by 40 cycles of PCR
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Standard curves were generated and the relative amount
of target gene mRNA was normalized to GAPDH. Spe-
cificity was verified by melt curve analysis and agarose
gel electrophoresis. Data normalization and analysis an
endogenous control, GAPDH present on the PCR was
used for normalization. Each replicate cycle threshold
(CT) was normalized to the average CT of endogenous
control on a sample basis. The comparative CT method
was used to calculate the relative quantification of gene
expression. The following formula was used to calculate
the relative amount of the transcripts in the gastric can-
cer samples and the control group, both of which were
normalized to the endogenous control. ΔΔCT = ΔCT
(gastric cancer)- ΔCT (control) for RNA samples. ΔCT
i st h el o g 2d i f f e r e n c ei nC Tb e t w e e nt h et a r g e tg e n e s
and endogenous controls by subtracting the average CT
of controls from each replicate. The fold change for
each gastric cancer sample relative to the control sample
=2
-ΔΔCT. When the expression showed a 2-fold increase
or decrease compared with normal counterpart tissue, it
was considered as an altered expression.
Statistical analysis
All statistical analyses were done by SPSS 15.0 software
package. Two-tailed P value less than 0.05 was consid-
ered statistically significant. In the set of RT-PCR analy-
sis of fresh tumors and paired normal tissues, the ratio
of Bmi-1 and Mel-18 mRNA expression was not nor-
mally distributed. Hence, the distribution was estab-
lished by using Log10, and geometric averages. The
correlation between Bmi-1 and Mel-18 expression levels
was analyzed by the Pearson coefficient test. The corre-
lation between Bmi-1 or Mel-18 expression and clinico-
pathologic characteristics was analyzed by ANOVA.
Results
Expression of Bmi-1 and Mel-18 at mRNA level inversely
correlates in gastric tumors
Our previous data showed an inverse correlation
between Bmi-1 and Mel-18 expression in breast cancer
cells and breast cancer tissues. Based on these data, we
hypothesized that gastric cancer may also express high
Bmi-1 and low Mel-18. To probe this hypothesis, we
studied the expression of Mel-18 and Bmi-1 in gastric
tumors by QRT-PCR. QRT-PCR analysis showed that
35 of 71 (49.3%) fresh gastric tumor tissues overex-
pressed Bmi-1, and 46 of 71 (64.79%) expressed low
levels of Mel-18, compared with paired normal gastric
mucosal tissues. (Table 1, Figure 1).
The correlation between Bmi-1 and Mel-18 expression
at mRNA level was further analyzed by the Pearson
coefficient correlation analysis, which showed a strong
negative correlation (r = - 0.252, P = 0.034).
The correlation between the expression of Mel-18 or Bmi-
1 with clinicopathologic characteristics
We found a significant positive correlation between
Bmi-1 overexpression and tumor size, depth of invasion
(T classification), or lymph node metastasis (N classifi-
cation). The expression of Bmi-1 was higher in the
patients with bigger tumor, deeper invasion, or positive
lymph node metastasis. We also found that there was a
significant negative correlation between Mel-18 expres-
sion with lymph node metastasis or the clinical stage. Its
expression was lower in the patients with lymph node
metastasis, or late stage disease (Table 2).
Discussion
Mammalian PcG protein complexes are generally classi-
fied into two distinct types: Polycomb repressive com-
plexes 1 and 2 (PRC1 and PRC2). Mel-18 protein
product is a constituent of mammalian PRC1 together
with M33, Bmi-1 or rae28/Mph-1, and Scmh1 [1,44-47].
In human tumors, some reports have showed alterations
in PcG expression, in such human hematologic malig-
nancies as nodal B-cell lymphomas [48,49], mantle cell
lymphomas [23,50], and Hodgkin’sl y m p h o m a s
[13,51,52].It has been reported that solid tumors, such
as lung cancers [53],medulloblastomas [3], liver [54],
penis [55], breast [28,56],colon [57], and prostate carci-
nomas [58], also display disturbed PcG gene expression.
Bmi-1 is one of the most important PcG proteins that
is known to regulate proliferation and senescence in
mammalian cells, and plays an important role in self-
renewal of stem cells. It can not only immortalize
human mammary epithelial cells (HMECs) [27], but also
can cooperate with H-Ras to transform HMECs and
transform keratinocytes [59,60]. Abnormal expression of
Bmi-1 has been found in several human cancers and its
overexpression is often correlated with poor prognosis
in many types of malignances [28-34]. Overexpression
of Bmi-1 in gastric cancer has been previously reported
[32,61]. It was found that Bmi-1 overexpression was
highly correlated with tumor size, clinical stage, lymph
node metastasis and T classification [32]. In another
study, Bmi-1 expression was closely related with the
Lauren’s and Borrmann’s classification and clinical stage
in gastric cancer [61]. We also found that gastric tumor
tissues expressed significantly higher Bmi-1, and Bmi-1
overexpression correlated with lymph node metastasis,
or clinical stage, which was accordance with the results
in in vitro study that knockdown of Bmi-1 expression
was accompanied by decreased transformed phenotype
and migration ability in gastric cancer cell lines [33]. In
these studies Bmi-1 was detected at protein level by
IHC method. Here we detected Bmi-1 at mRNA level
by QRT-PCR method and found that Bmi-1 is overex-
pressed in gastric tumors and Bmi-1 overexpression
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cation), or lymph node metastasis (N classification),
which confirms previous observation of Bmi-1 at protein
level. It suggests that Bmi-1 may play a crucial role and
act as an oncogene in gastric cancer, and associated
with the carcinogenesis, progression, and metastasis of
gastric cancer.
Mel-18 was originally cloned from B16 mouse mela-
noma cells [62]. Mel-18 may bind to the nucleotide
sequence 5’-GACTNGACT-3’, which is present in the
promoter region of certain genes. One of the unique
target genes of Mel-18 is c-Myc transcriptionally
repressed by Mel-18. In mature resting B cells, Mel-18
negatively regulates B cell receptor-induced proliferation
through the down-regulation of the c-Myc/cdc25 cas-
cade [63,64]. Our previous studies suggest that Mel-18
is a physiologic regulator of Bmi-1 expression and tran-
scriptionally down-regulates Bmi-1 expression during
senescence in human fibroblasts and acts as a tumor
suppressor in breast cancer [38,43]. Our previous data
also showed an inverse correlation between Bmi-1 and
Mel-18 expression at protein level in breast cancer and
gastric cancer [33,38]. However, there was no correla-
tion between Mel-18 expression at protein level and
clinicopathological factors in in vivo study, which was
not accordance with the results in in vitro study that
Mel-18 overexpression was accompanied by decreased
transformed phenotype and migration ability in gastric
cancer cell lines[33]. One of the reasons may due to the
reliability of IHC method depends on the specific of
antibody. Mel-18 antibody is rabbit polyclonal and it’s
specific is not so good as Bmi-1 antibody which is
mouse monoclonal. So we suspect the results of Mel-18
expression in tumor tissues at protein level detected by
IHC may be not too reliable. To clarify this problem
and further explore the role of Mel-18 in gastric cancer,
Table 1 Frequencies of altered expression of Bmi-1 and Mel-18 in the 71 gastric cancer tissues
Gene Decreased expression Normal expression Overexpression
Frequency Percentage Frequency Percentage Frequency Percentage
Bmi-1 9 12.68% 27 38.03% 35 49.30%
Mel-18 46 64.79% 20 28.17% 5 7.04%
Figure 1 Comparative expression levels of Bmi-1 or Mel-18 were shown in 71 normal mucosal tissues and paired gastric cancer
samples.A :Bmi-1 gene expression in human gastric cancer. B: Mel-18 gene expression in human gastric cancer. Expression level of target genes
was displayed in a relative quantification method as a ratio between it in tumor tissues and that in normal tissues in the amounts of RNA. The
expression level of Bmi-1 or Mel-18 in normal tissues was treated as 1 and the ratio of gene expression was the expression level of Bmi-1 or Mel-
18 in tumor tissues.
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in the present study. We found that most gastric tumor
tissues (64.79%) expressed decreased mRNA levels of
Mel-18, and there was a strong negative correlation
between Bmi-1 and Mel-18 expression at mRNA level.
The results confirm the expression of Mel-18 and its’
relationship with Bmi-1 at protein level in our previous
study. More important, we also found that decreased
expression of Mel-18 correlated with lymph node metas-
tasis or the clinical stage, which was accordance with
the results in in vitro study that Mel-18 overexpression
was accompanied by decreased transformed phenotype
and migration ability in gastric cancer cell lines in our
previous study[33]. It provides more convincing in vivo
data to suggest that Mel-18 m a yp l a yac r u c i a lo p p o s i t e
role to Bmi-1 and act as a tumor suppressor in gastric
cancer, and associated with the carcinogenesis, progres-
sion, and metastasis of gastric cancer.
In the current study we demonstrated that neoplastic
cells in gastric cancer can’t normally express Bmi-1 and
Mel-18. We propose that abnormal PcG expression
results in an altered composition of the PRC1 in gastric
cancer cells, which probably affects expression of target
genes involved in regulation of senescence and/or the
cell cycle. Our observations add to the increasing evi-
dence that PcG genes are very important contributors to
the carcinogenesis and progression of human tumors.
We additonally found that both Mel-18 and Bmi-1 cor-
related with lymph node metastasis. The mechanisms
that they regulate cancer cells metastasis need to be
further studied.
This research is the first time to study the correlation
between Mel-18 or Bmi-1 expression at mRNA level
and clinicopathological characteristics of gastric cancer
by quantitative method. The expression of Bmi-1 and
Mel-18 was correlated with gastric cancer progress,
advanced gastric cancer more likely expressed higher
Bmi-1 and lower Mel-18. Its clinical value deserves
further study in a larger patient population.
Conclusions
In conclusion, our results suggest that Bmi-1 and
Mel-18 are coordinately deregulated. Interestingly, we
observed a reverse correlation between the expression
levels of Bmi-1 and Mel-18 in gastric cancer. Both
Bmi-1 and Mel-18 are involved in the development and
progression of gastric cancer. Bmi-1 and Mel-18 might
be novel molecular markers for gastric cancer. But,the
detailed mechanisms of regulation of Bmi-1 and Mel-18
remained to be elucidated.
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